Clinical Transplantation

Cover image for Vol. 32 Issue 2

Edited By: Ron Shapiro, MD

Impact Factor: 1.865

ISI Journal Citation Reports © Ranking: 2016: 16/25 (Transplantation); 97/197 (Surgery)

Online ISSN: 1399-0012

Just Published Articles

  1. Which is more nephrotoxic for kidney transplants: BK nephropathy or rejection?

    Sandesh Parajuli, Brad C. Astor, Dixon Kaufman, Brenda Muth, Maha Mohamed, Neetika Garg, Arjang Djamali and Didier A. Mandelbrot

    Version of Record online: 23 FEB 2018 | DOI: 10.1111/ctr.13216

  2. Elevated donor plasminogen activator inhibitor-1 levels and the risk of primary graft dysfunction

    Barbara C. S. Hamilton, Gabriela R. Dincheva, Hanjing Zhuo, Jeffrey A. Golden, Marek Brzezinski, Jonathan P. Singer, Michael A. Matthay and Jasleen Kukreja

    Version of Record online: 23 FEB 2018 | DOI: 10.1111/ctr.13210

  3. Outcomes at 7 years post-transplant in black versus non-black kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT

    Sander Florman, Flavio Vincenti, Antoine Durrbach, Marwan Abouljoud, Barbara Bresnahan, Valter Duro Garcia, Laura Mulloy, Kim Rice, Lionel Rostaing, Carlos Zayas, Kellie Calderon, Ulf Meier-Kriesche, Martin Polinsky, Lingfeng Yang, Jose Medina Pestana and Christian P. Larsen

    Accepted manuscript online: 20 FEB 2018 10:00AM EST | DOI: 10.1111/ctr.13225

  4. Recurrent IgA nephropathy after renal transplantation and steroid withdrawal

    Maria Cristina Di Vico, Maria Messina, Fabrizio Fop, Antonella Barreca, Giuseppe Paolo Segoloni and Luigi Biancone

    Version of Record online: 20 FEB 2018 | DOI: 10.1111/ctr.13207

  5. Impact of the Kidney Allocation System on Young Pediatric Recipients

    W F Parker, L F Ross, J R Thistlethwaite Jr and A E Gallo

    Accepted manuscript online: 19 FEB 2018 02:25AM EST | DOI: 10.1111/ctr.13223


CTR | Transplant Peer Review Network


Clinical Transplantation participates in the Wiley Transplant Peer Review Network

Download today | Clinical Transplantation app

CTR app

Available in the App StoreSM: iPad®, iPhone®, and iPod touch®
Subscribers: follow the registration wizard for full access.

In Memoriam


The Legacy of Thomas E. Starzl, MD, PhD 3/11/1926 – 3/4/2017

One of the great pioneers (some would argue the greatest pioneer) in the history of transplantation passed away in his sleep in the early morning of March 4, 2017, one week shy of his 91st birthday. His accomplishments would have been enough for any 6 incredibly productive careers—over 2200 papers, 1300 lectures, several books, and critical roles in the development of clinical immunosuppression, kidney, liver, pancreas, and small bowel transplantation, and the mentorship of generations of leaders in the field of transplantation. A member of every important surgical and medical society, including the Institute of Medicine and the American Philosophical Society, he received virtually every award imaginable, including the National Medal of Science, the Lasker award, and the Medawar Prize (of the Transplantation Society), with the exception of the Nobel Prize (for which he had been nominated). His contributions to the development of clinical immunosuppression began with the demonstration that azathioprine and prednisone represented a successful approach in kidney transplantation, at a time when any sort of routine engraftment had not yet been achieved. He continued with the demonstration of the efficacy of cyclosporine in liver, kidney, heart, lung, and pancreas transplantation, and the improved efficacy of tacrolimus as an immunosuppressive agent, allowing routine withdrawal or even avoidance of corticosteroids. His perseverance led to the first successful liver transplants, at a time when few shared his conviction that it was achievable. His demonstration of micro chimerism in long surviving kidney recipients and his attempts at tolerogenic immunosuppression and xenotransplantation reflected the diversity of his scientific interests.

There were, however, two fundamental aspects of his world view that directed all of his endeavors, and that remain lessons and a legacy for all of us. First, he was fundamentally a clinician, and everything that he did was focused on improving the welfare of his patients. He celebrated their successes, and mourned their deaths. Second, and perhaps most important, he was never satisfied. Everything could be improved—immunosuppression, technical approaches, minimization of side effects—and he was never complacent about what had been achieved. This unwillingness to accept what had been achieved as the last word was pervasive throughout his career, and drove him to continue to improve everything he touched. His lack of complacence remains an ongoing challenge for those of us who have continued in the field.

Dr. Starzl was an important mentor to just about everyone in the field of transplantation, either directly, or one or two generations removed. His record of accomplishment is humbling to the rest of us, and he is a role model for his dedication and perseverance in the face of criticism and active hostility (new ideas are never easily accepted, and he generated new ideas throughout his career). He will be missed by all of us who knew him and all of the patients whose lives he saved and enriched.

New Content Alerts

Never miss an issue of Clinical Transplantation!

E Alerts

Free, customizable e-mail content alerts notify you of articles or issues as they publish, in the frequency and format you prefer. Sign up today and never miss an issue.

content alertAlerts: Log in (top right), then click this icon in the Journal Tools menu (left).

Read A Sample Issue Today!

Sample Issues Available

Did you know that you can download all the articles from the January 2016 issue for free? Check it out today!